Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryohei Katayama

Showing results (31-40 of 107) with videos related to

Pageof 11
Sort By:
Scientific Reports|February 9, 2020
Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation methodFumie Ono, Shuntaro Chiba, Yuta Isaka, et al.
NPJ Precision Oncology|January 6, 2025
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localizationKohei Maruyama, Yuki Shimizu, Yumi Nomura, et al.
Acta Biomaterialia|July 7, 2024
Promoting biological similarity by collagen microfibers in 3D colorectal cancer-stromal tissue: Replicating mechanical properties and cancer stem cell markersNaoko Sasaki, Yoshiya Asano, Yukiko Sorayama, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2020
Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphismsRyo Ariyasu, Noriko Yanagitani, Kenichi Tadokoro, et al.
Cancer Research|April 20, 2013
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibitionRyohei Katayama, Aki Aoyama, Takao Yamori, et al.
Molecular Oncology|October 6, 2024
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancerKoh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancerRyohei Katayama, Yuka Kobayashi, Luc Friboulet, et al.
Cancer Letters|September 7, 2024
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancerXinzhao Wei, Ken Uchibori, Nobuyuki Kondo, et al.
Acta Biomaterialia|September 12, 2025
Engineering a multilayered 3D stromal barrier model for quantitative analysis of T cell infiltration and cytotoxicityRii Morimura, Isana Nada, Yuka Mizue, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2023
Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancerMizuki Haraguchi, Kazuma Kiyotani, Tomohiro Tate, et al.
Pageof 11

Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Scientific Reports|February 9, 2020
Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation methodFumie Ono, Shuntaro Chiba, Yuta Isaka, et al.
NPJ Precision Oncology|January 6, 2025
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localizationKohei Maruyama, Yuki Shimizu, Yumi Nomura, et al.
Acta Biomaterialia|July 7, 2024
Promoting biological similarity by collagen microfibers in 3D colorectal cancer-stromal tissue: Replicating mechanical properties and cancer stem cell markersNaoko Sasaki, Yoshiya Asano, Yukiko Sorayama, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2020
Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphismsRyo Ariyasu, Noriko Yanagitani, Kenichi Tadokoro, et al.
Cancer Research|April 20, 2013
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibitionRyohei Katayama, Aki Aoyama, Takao Yamori, et al.
Molecular Oncology|October 6, 2024
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancerKoh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancerRyohei Katayama, Yuka Kobayashi, Luc Friboulet, et al.
Cancer Letters|September 7, 2024
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancerXinzhao Wei, Ken Uchibori, Nobuyuki Kondo, et al.
Acta Biomaterialia|September 12, 2025
Engineering a multilayered 3D stromal barrier model for quantitative analysis of T cell infiltration and cytotoxicityRii Morimura, Isana Nada, Yuka Mizue, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2023
Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancerMizuki Haraguchi, Kazuma Kiyotani, Tomohiro Tate, et al.
Pageof 11